Obituary – Anders Ekbom
Jonas Ludvigsson,Johan Askling,Sven Cnattingius,Per Hall,Lars Klareskog,Olof Nyren,John Baron,Henrik Sørensen
DOI: https://doi.org/10.2147/clep.s490837
2024-09-02
Clinical Epidemiology
Abstract:Jonas F Ludvigsson, 1 Johan Askling, 1 Sven Cnattingius, 1 Per Hall, 1 Lars Klareskog, 1 Olof Nyren, 1 John A Baron, 2 Henrik Toft Sørensen 3 1 Karolinska Institutet, Solna, Sweden; 2 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 3 Aarhus University, Aarhus, Denmark Correspondence: Jonas F Ludvigsson, Email Anders Ekbom (1947–2024) , surgeon and Professor of Epidemiology, died on 29 July 2024 at the age of 76 years. During his almost 50 years as a clinician and investigator, he made substantial contributions to international science and clinical practice. Ekbom began studying medicine in Lund, in southern Sweden. Initially, he also studied theology, law, economics and engineering. He later graduated from Uppsala University Medical School and soon embarked on a surgical career, which led him to the Department of Surgery at Uppsala University Hospital. He qualified as a general surgeon in 1984. His clinical interests mainly concerned gastrointestinal surgery, particularly for inflammatory bowel disease and colorectal cancer, but also for diseases of the pancreas and biliary tract. He became a highly proficient endoscopist and performed numerous endoscopic retrograde cholangiopancreatographies. Ekbom also had an interest in coeliac disease. He liked to mention a lecture he gave to Swedish gastroenterologists in the 1980s: "Upper endoscopy, why stop at the pylorus?", in which he argued that patients with abdominal symptoms should be examined for coeliac disease. It was only in the late 1980s that Ekbom began his scientific (and epidemiological) career under professor Hans-Olov Adami's supervision. When Adami's research group moved from Uppsala to Karolinska Institutet in 1997, Ekbom followed. Two years later he was appointed full professor there, and he soon established his own research group, the Clinical Epidemiology Unit, known by its Swedish acronym "KEP". The unit belonged to both Karolinska Institutet and to the nearby Karolinska University Hospital, a unique feature that reflected Ekbom ́s conviction that research must be anchored in clinical practice. Ekbom was Head of the Department of Medicine for a number of years and was later asked to join the Karolinska Institutet leadership. Although he left clinical practice in the 1990s, Ekbom continued to engage in clinical questions and was often asked by the media to comment on healthcare issues. He served as an expert on the Swedish Corona Commission, and in 2006 led the scientific misconduct committee examining the research fraud of Jon Sudbø in Norway. 1 Ekbom later became the Chair of the Karolinska Institutet Ethics Council and became Karolinska's first "ombudsman", tasked to provide mentorship in research ethics. He was also engaged in international research collaboration and participated in several major Nordic studies 2–4 and evaluation tasks for several universities. When at the end of his career asked of his proudest moments in research, he mentioned four: His early papers on colorectal cancer risk in inflammatory bowel disease, published in the New England Journal of Medicine 5 and the Lancet, 6 in which he used nationwide registers to calculate relative risks of cancer and to identify risk groups for colorectal cancer that potentially require extra surveillance. Ekbom later became an appreciated member of IOIBD-International Organization for the Study of Inflammatory Bowel Disease. Ten years later, with his then PhD student, now Professor, Johan Askling, Ekbom explored the role of heredity for colorectal cancer risk in patients with inflammatory bowel disease. 7,8 In a paper published in Gastroenterology, 7 he suggested that having a first-degree relative with colorectal cancer diagnosed before the age of 50 years was a particularly strong risk factor. This finding has since been incorporated into clinical guidelines and patient information resources. 9 In collaboration with Professor Lars Klareskog, Ekbom studied the role of inflammation in carcinogenesis. Together with Assoc. Professor Eva Baecklund et al, 10,11 they demonstrated that the risk of lymphoma in patients with rheumatoid arthritis was intimately connected to the degree of inflammation. This last finding was a natural starting point for the study of anti-inflammatory treatment in chronic diseases, beginning with anti-tumour necrosis factor (TNF)-alpha therapy. 12 At the dawn of biologics, there was a widespread fear that their side-effects would be so severe as to hinder their use. Ekbom et al used Swedish health care registers to establish an internationally unique safety surveillance system that has helped new therapies to be safely and broadly implemented. Ekbom also con -Abstract Truncated-
public, environmental & occupational health